NCT01599611

Brief Summary

The objective of this study was to investigate whether infants with total serum bilirubin \> 450 umol/L in the neonatal period and no symptoms or no more than early acute bilirubin encephalopathy develop long term sequelae with impairment of motor development, hearing and executive function compared with a control group.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
128

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2010

Shorter than P25 for all trials

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2010

Completed
10 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2011

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2011

Completed
1.4 years until next milestone

First Submitted

Initial submission to the registry

May 14, 2012

Completed
2 days until next milestone

First Posted

Study publicly available on registry

May 16, 2012

Completed
Last Updated

May 16, 2012

Status Verified

May 1, 2012

Enrollment Period

10 months

First QC Date

May 14, 2012

Last Update Submit

May 15, 2012

Conditions

Keywords

Neonatal hyperbilirubinemiaFollow-upMotor developmentHearingExecutive function

Outcome Measures

Primary Outcomes (1)

  • Motor development

    Delayed motor development for children in the exposed group compared to children in the non-exposed group

    Age 5-10 years

Study Arms (2)

Exposed group

Children age 5-10 years old who had a total serum bilirubin \> 450 umol/L in the neonatal period

Procedure: Movement assessment battery for children - 2

Non-exposed group

Matched 1:1 to the exposed group on gender, age, gestational age and municipality of residence

Procedure: Movement assessment battery for children - 2

Interventions

A standardised test developed to identify developmental difficulties in children.

Also known as: MABC-2
Exposed groupNon-exposed group

Eligibility Criteria

Age5 Years - 10 Years
Sexall
Healthy VolunteersNo
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

All children born in Denmark in the period 01.01.2000 - 31.12.2005 with a gestational age \>= 35 weeks and a total serum bilirubin \> 450 umol/L and a matched control group of children

You may qualify if:

  • Gestational age \> 35 weeks
  • Total serum bilirubin \> 450 umol/L in the neonatal period
  • Born in the period 01.01.2000 - 31.12.2005

You may not qualify if:

  • Acute intermediate or advanced bilirubin encephalopathy

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Vandborg PK, Hansen BM, Greisen G, Mathiasen R, Kasper F, Ebbesen F. Follow-up of extreme neonatal hyperbilirubinaemia in 5- to 10-year-old children: a Danish population-based study. Dev Med Child Neurol. 2015 Apr;57(4):378-84. doi: 10.1111/dmcn.12603. Epub 2014 Oct 29.

Related Links

MeSH Terms

Conditions

Hyperbilirubinemia, Neonatal

Condition Hierarchy (Ancestors)

Infant, Newborn, DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesHyperbilirubinemiaPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Pernille Vandborg, MD, PhD

    Børneafdelingen, Aalborg Sygehus, Denmark

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 14, 2012

First Posted

May 16, 2012

Study Start

March 1, 2010

Primary Completion

January 1, 2011

Study Completion

January 1, 2011

Last Updated

May 16, 2012

Record last verified: 2012-05